News | December 10, 2023
Pfizer presents marstacimab Phase 3 Data at ASH 2023
Demonstrate significant bleed reduction in hemophilia A and B
Demonstrate significant bleed reduction in hemophilia A and B
New facility is part of Aptar Pharma’s global expansion program
There has been no loss or injury to human life
Conditional marketing authorization is based on clinically meaningful response rates, duration of response, and safety from the Phase 2 MagnetisMM-3 trial
Methylene blue is a cationic thiazine dye that necessitates specialised capabilities and expertise to develop and manufacture the product
The current annual U.S. market for Sildenafil for Oral Suspension is approximately $43 million
Ivabradine Tablets, 5 mg and 7.5 mg had annual sales of USD 136.5 mn in the United States
The workshop is specially curated for Ayurvedic medical officers from Delhi and Haryana
The full transition of Viatris' biosimilars operations to Biocon Biologics in Europe represents another significant milestone
Almost 300 million people globally have chronic hepatitis B
Subscribe To Our Newsletter & Stay Updated
